David M. Thomas

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

David M. Thomas, Robert M. Henshaw, Keith M. Skubitz et al. · The Lancet Oncology · 2010 · 703 citations

Bone Disease, Malignant Disease, Medicine +7

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

Sant P. Chawla, Robert M. Henshaw, Leanne L. Seeger et al. · The Lancet Oncology · 2013 · 573 citations

Bone Disease, Interim Analysis, Surgical Oncology +9

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 454 citations · Full text

Surgical Oncology, Oncology, Medicine +9

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel et al. · Clinical Cancer Research · 2012 · 425 citations · Full text

Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis

Michael Glantz, Suzanne LaFollette, Kurt A. Jaeckle et al. · Journal of Clinical Oncology · 1999 · 398 citations